Navigation Links
Erectile dysfunction in diabetes is due to selective defect in the brain

A new study sheds additional light on how erectile dysfunction (ED) interacts with diabetes. The study is another step in uncovering the link between the two disorders, and may lead to improved efficacy in treatments.

The study, "Lack of Central Nitric Oxide Triggers Erectile Dysfunction in Diabetes," was conducted by Hong Zheng, William G. Mayhan, and Kaushik P. Patel, Departments of Cellular and Integrative Physiology; and Keshore R. Bidasee, Department of Pharmacology, University of Nebraska Medical Center, Omaha, NE. The results appear in the March 2007 edition of the American Journal of Physiology ?Regulatory, Integrative and Comparative Physiology, one of 11 peer-reviewed scientific publications issued monthly by The American Physiological Society (APS) (


Sexual dysfunction is a well-recognized consequence of diabetes mellitus in men. Erectile dysfunction, retrograde ejaculation and the loss of seminal emission have all been described by such patients. This study examined induced penile erection, yawning and stretch in diabetic rats. Male Sprague-Dawley rats treated with streptozotocin (STZ) to induce diabetes were used as they exhibit sexual and behavioral symptoms similar to those found in diabetic men with sexual dysfunction.

The researchers focused on the paraventricular nucleus (PVN) of the hypothalamus, located in the brain, an integration center between the central and peripheral nervous systems. The site is involved in numerous functions, including erectile function and sexual behavior, and is a primary site within the forebrain that has been implicated in penile erection. The investigators also examined central nitric oxide (NO within the PVN) which plays an important role in the neurotransmission of normal penile erection.

Penile erection is a behavioral response that occurs in response to the administration of N-methyl-D-aspar tic acid (NMDA) within the PVN. At the same time, inhibition of NO synthase with NG-monomethly-L-argining (L-NMMA) prevents NMDA-induced erection. The researchers hypothesized that the blunted NMDA mediated responses in diabetes reflects an impaired NO mechanism within the PVN. The involvement of an NO mechanism in the NMDA mediated behavioral response was also explored.


The rats were exposed to a light/dark cycle, with standard temperature and humidity levels. The animals were randomly selected to receive chemical injection of the streptozotocin (STZ) to induce diabetes. Those rats that did not receive STZ (vehicle injected) served as controls. The experiments began on each of the rats four weeks after the injections.

Four experiments were conducted. Experiment one examined the effect of L-NMMA on NMDA mediated behavioral responses in normal rats; experiment two measured behavioral responses to NMDA or sodium nitroprusside (SNP), an NO donor in both control and diabetic rats; the third experiment observed the effect of diabetes on nNOS protein in the PVN; the fourth experiment measured NMDA mediated behavioral responses in diabetic rats after restoring the nNOS protein in the PVN using viral gene transfer.


The researchers found that:

  • when L-NMMA was used to block NO production in the PVN, NMDA mediated penile erectile responses were blunted

  • NMDA-induced erections were significantly blunted in diabetic rats compared with control rats

  • the nNOS protein levels in the PVN were decreased in rats with diabetes and

  • restoring nNOS protein within the PVN of diabetic rats with viral gene transfer could alleviate the blunted NMDA induced erectile responses.


The researchers conclude that erectile dysfunction in diabetes is due to a selective defect in the NO mechanisms within the P VN. This defect is a loss in the synthetic enzyme for the production of NO within the neurons of the PVN. Restoring this synthetic enzyme may have a significant therapeutic value for diabetic patients with ED.

Source:American Physiological Society

Related biology news :

1. Erectile dysfunction drugs heighten natural anti-cancer activity
2. Study of gene transfer for erectile dysfunction shows promise
3. Protein may hold key to decreasing organ dysfunction rates in heart transplants
4. Chemists identify key gene in development of type 1 diabetes
5. Rare surgery performed to remove pancreas, prevent diabetes
6. Future diabetes drugs may target new protein interaction
7. Malfunctioning bone marrow cells sabotage nerve cells in diabetes
8. New imaging technology shown to detect pancreatic inflammation in type 1 diabetes
9. UCSD study clarifies insulins role in blocking release of energy in patients with type II diabetes
10. Researchers reverse juvenile diabetes in animal model
11. Infused spleen cells found not to impact islet recovery and reversal of type 1 diabetes in mice

Post Your Comments:

(Date:9/30/2015)... 2015  The U.S. Court of Appeals for the ... in favor of Crossmatch ™, affirming the International ... Suprema and its U.S. partner Mentalix violated Section 337 ... that declares it unlawful to engage in "unfair practices" ... Crossmatch,s patents, the 5,900,993 patent and the 7,203,344 patent. ...
(Date:9/29/2015)... News facts: ... energy , Minimized design shrinks PC footprint ... and embedded Fujitsu PalmSecure authentication enable enterprises to realize ... shows that good things come in small packages, with ... enterprise desktop and mobile portfolio. Featuring workplace design that ...
(Date:9/28/2015)... , Sept. 28, 2015 ... today that its expedited traveler service is ... platform transforms travel, bringing a frictionless experience, ... members. "CLEAR offers our travelers ... customer service," said Jim Smith , ...
Breaking Biology News(10 mins):
(Date:10/9/2015)... , ... October 09, 2015 , ... ... However, the current methods of separating those cells from their surroundings for research, ... to the cells. , To address this, Ann Arbor-based startup Akadeum Life ...
(Date:10/8/2015)... WEST PALM BEACH, Fla. , Oct. 8, 2015 ... a leader in synthetic biology, today announced the appointment ... President, Head of Environment Sector, succeeding Nir Nimrodi ... Corporate Development.  Mr. Vaillancourt will direct Intrexon,s endeavors to ... North America , where he held ...
(Date:10/8/2015)... 8, 2015  ATCC, the premier global biological materials ... been selected by The Michael J. Fox Foundation for ... academic, pharmaceutical, and biotechnology organizations committed to speed a ... United States , and more than 5 million ... United States , and more than 5 million ...
(Date:10/8/2015)... , October 8, 2015 ...   --> Goldman Small Cap Research, ... small cap and microcap sectors, announced today that ... on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a ... developing and preparing treatments for cancer and diabetes. ...
Breaking Biology Technology: